BRAINSTORM CELL THERAPEUTICS INC. (BCLI) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.61M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.05M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.05M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.57M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$3.61M | (m) | (m) | (m) | (m) | -$895.00K | (m) | $963.00K | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$2.05M | (m) | (m) | (m) | (m) | -$1.32M | (m) | $762.00K | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$2.05M | (m) | (m) | (m) | (m) | -$1.10M | (m) | $899.00K | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$2.57M | (m) | (m) | (m) | (m) | -$3.50M | (m) | $1.12M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$3.09M | (m) | (m) | (m) | (m) | -$1.63M | (m) | $1.30M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$3.05M | (m) | (m) | (m) | (m) | -$3.30M | (m) | $1.04M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$2.98M | (m) | (m) | (m) | (m) | -$1.68M | (m) | $922.00K | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$2.47M | (m) | (m) | (m) | (m) | -$3.06M | (m) | $961.00K | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$6.04M | (m) | (m) | (m) | $18.00K | -$6.41M | (m) | $3.33M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$5.45M | (m) | (m) | (m) | (m) | -$6.78M | (m) | $2.79M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$5.15M | (m) | (m) | (m) | (m) | -$3.99M | (m) | $2.92M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$6.84M | (m) | (m) | (m) | $1.00K | -$4.85M | (m) | $3.78M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$7.59M | (m) | (m) | (m) | $19.00K | -$6.13M | (m) | $5.11M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$5.47M | (m) | (m) | (m) | $9.00K | -$3.69M | (m) | $2.62M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$5.28M | (m) | (m) | (m) | $237.00K | -$6.46M | (m) | $3.62M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$6.12M | (m) | (m) | (m) | $28.00K | -$5.33M | (m) | $3.60M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$6.93M | (m) | (m) | (m) | $30.00K | -$8.97M | (m) | $4.34M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$4.49M | (m) | (m) | (m) | $88.00K | -$6.92M | (m) | $1.87M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$7.40M | (m) | (m) | (m) | $50.00K | -$5.66M | (m) | $5.69M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$8.31M | (m) | (m) | (m) | $7.00K | -$15.03M | (m) | $5.95M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$5.55M | (m) | (m) | (m) | $102.00K | -$3.63M | (m) | $4.01M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$4.86M | (m) | (m) | (m) | $21.00K | -$3.51M | (m) | $3.55M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$4.93M | (m) | (m) | (m) | $4.00K | -$835.00K | (m) | $3.46M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$3.23M | (m) | (m) | (m) | $1.00K | -$6.59M | (m) | $1.98M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$3.09M | (m) | (m) | (m) | $215.00K | $55.00K | (m) | $1.48M | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$2.31M | (m) | (m) | (m) | $45.00K | -$2.13M | (m) | $977.00K | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$2.39M | (m) | (m) | (m) | $86.00K | $3.84M | (m) | $1.17M | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$1.07M | (m) | (m) | (m) | $32.00K | -$1.63M | (m) | $435.00K | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$1.77M | (m) | (m) | (m) | $0.00 | -$1.64M | (m) | $941.00K | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$1.64M | (m) | (m) | (m) | $11.00K | (m) | (m) | $790.00K | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$983.00K | (m) | (m) | (m) | $59.00K | (m) | (m) | $151.00K | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$1.81M | (m) | (m) | (m) | $26.00K | (m) | (m) | $986.00K | (m) | (m) |
| 2015-09-30 | Reported | (m) | -$2.57M | (m) | (m) | (m) | $12.00K | (m) | (m) | $1.50M | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$2.36M | (m) | (m) | (m) | -$16.00K | (m) | (m) | $1.38M | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$2.21M | (m) | (m) | (m) | $0.00 | -$1.94M | (m) | $1.25M | (m) | $0.00 |
| 2014-09-30 | Reported | (m) | -$2.43M | (m) | (m) | (m) | $0.00 | -$1.12M | (m) | $1.57M | (m) | $2.00K |
| 2014-06-30 | Reported | (m) | -$1.29M | (m) | (m) | (m) | $0.00 | -$970.00K | (m) | $877.00K | (m) | $0.00 |
| 2014-03-31 | Reported | (m) | -$2.11M | (m) | (m) | (m) | $94.00K | -$391.00K | (m) | $680.00K | (m) | $0.00 |
| 2013-09-30 | Reported | (m) | -$1.08M | (m) | (m) | (m) | $31.00K | -$713.00K | (m) | $804.00K | (m) | $1.00K |
| 2013-06-30 | Reported | (m) | -$1.50M | (m) | (m) | (m) | $46.00K | -$1.06M | (m) | $742.00K | (m) | $18.00K |
| 2013-03-31 | Reported | (m) | -$1.08M | (m) | (m) | (m) | $20.00K | -$670.00K | (m) | $522.00K | (m) | $0.00 |
| 2012-09-30 | Reported | (m) | -$1.15M | (m) | (m) | (m) | $14.00K | -$1.07M | (m) | $732.00K | (m) | $0.00 |
| 2012-06-30 | Reported | (m) | -$829.00K | (m) | (m) | (m) | $9.00K | -$419.00K | (m) | $385.00K | (m) | $1.00K |
| 2012-03-31 | Reported | (m) | -$868.00K | (m) | (m) | (m) | $52.00K | -$746.00K | (m) | $369.00K | (m) | $4.00K |
| 2011-09-30 | Reported | (m) | -$694.00K | (m) | (m) | (m) | $1.00K | -$897.00K | (m) | $176.00K | (m) | $0.00 |
| 2011-06-30 | Reported | (m) | $1.09M | (m) | (m) | (m) | $0.00* | -$800.00K* | (m) | $586.00K | (m) | -$5.00K |
| 2011-03-31 | Reported | (m) | $705.00K | (m) | (m) | (m) | $37.00K | -$55.00K | (m) | $270.00K | (m) | $0.00 |
| 2010-09-30 | Reported | (m) | $680.00K | (m) | (m) | (m) | $2.00K* | -$400.00K* | (m) | $371.00K | (m) | -$24.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$9.95M | (m) | (m) | (m) | (m) | -$6.97M | (m) | $4.17M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$11.69M | (m) | (m) | (m) | (m) | -$9.09M | (m) | $4.65M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$21.44M | (m) | (m) | (m) | $18.00K | -$20.46M | (m) | $10.75M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$24.82M | (m) | (m) | (m) | $29.00K | -$19.32M | (m) | $13.96M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$24.54M | (m) | (m) | (m) | $330.00K | -$26.27M | (m) | $15.23M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$31.68M | (m) | (m) | (m) | $378.00K | -$35.19M | (m) | $22.33M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$23.00M | (m) | (m) | (m) | $473.00K | -$11.25M | (m) | $17.20M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$14.06M | (m) | (m) | (m) | $369.00K | -$12.39M | (m) | $8.29M | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$5.00M | (m) | (m) | (m) | $180.00K | -$2.36M | (m) | $977.00K | (m) | $0.00 |
| 2016-12-31 | Reported | (m) | -$5.08M | (m) | (m) | (m) | $103.00K | -$5.86M | (m) | $2.25M | (m) | $0.00 |
| 2015-12-31 | Reported | (m) | -$8.54M | (m) | (m) | (m) | $45.00K | (m) | (m) | $4.95M | (m) | $0.00 |
| 2014-12-31 | Reported | (m) | -$7.42M | (m) | (m) | (m) | $161.00K | -$4.49M | (m) | $4.77M | (m) | $0.00 |
| 2013-12-31 | Reported | (m) | -$4.90M | (m) | (m) | (m) | $108.00K | -$4.05M | (m) | $2.92M | (m) | $0.00 |
| 2012-12-31 | Reported | (m) | -$3.42M | (m) | (m) | (m) | $90.00K | -$2.94M | (m) | $1.77M | (m) | $5.00K |
| 2011-12-31 | Reported | (m) | -$3.91M | (m) | (m) | (m) | $48.00K | -$2.22M | (m) | $1.69M | (m) | $5.00K |
| 2010-12-31 | Reported | (m) | $2.40M | (m) | (m) | (m) | $5.00K | -$2.07M | (m) | $1.04M | (m) | -$19.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |